Taken together, hyperuricemia associated with high PA, such as metabolic syndrome, may lead to the activation of URAT1 in cardiomyocytes, and a URAT1-selective inhibitor has a significant impact on PA-induced myocardial injury. Here, SLC22A12 is linked to metabolic syndrome.